CreditRiskMonitor is a financial risk analysis and news service for credit, supply chain and financial professionals.  Our strength in coverage spans 58,000 global public companies, totaling about $70 trillion in corporate revenue.  We also offer solutions that can help ease private company financial risk assessment.  Leading corporations around the world – including more than 35% of the Fortune 1000, plus thousands more worldwide – rely on us to help them stay ahead of financial risk quickly, accurately and cost-effectively. 

A partial report preview for Oncotelic Therapeutics Inc is shown below.  Where indicated by "Yes," CreditRiskMonitor contains this information in its extensive database.  To get access to the full report and learn more about CreditRiskMonitor's robust financial risk analysis and timely news service, request a personalized demo and free trial today.

If you are already a subscriber and want to access the full report, click here.

Oncotelic Therapeutics Inc
29397 Agoura Road Suite 107
Phone: (650) 635-7000p:650 635-7000 AGOURA HILLS, CA  91301  United States Ticker: OTLCOTLC
Business Summary
Oncotelic Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on developing drugs for the treatment of orphan oncology indications, developing antisense and small molecule injectable drugs for the treatment of cancer. The Company has eight primary drug and AI technology programs: AL-101, an intranasal drug and delivery system for intra-nasal Apomorphine for the treatment of Parkinson’s Disease (PD), erectile dysfunction (ED) and female sexual dysfunction (FSD); CA4P, a vascular disrupting agent (VDA) in combination with Ipilimumab for the treatment of solid tumors with focus on melanoma in adult and pediatric melanoma; Oxi4503, a second generation VDA for the treatment of liquid tumors with focus on childhood leukemia; OT-101, an antisense against TGF-ß2 for the treatment of various cancers and viruses, including SARS and the COVID-19, and Artemisini, a natural derivative from an Asian herb Artemisia Annua that inhibits the ability of various viruses to multiply.
(Source: 10-K)

Scores and Ratings
FRISK®
Score		 Z''
Score		 PAYCE®
Score		 DBT
Index		 Moody's
Rating		 Fitch
Rating		 DBRS
Rating
YesYes-----

Financials, News and Filings
Latest
Statement		 Last
Audit
News		 SEC
Filings		 Bankruptcy
Filings		 Suit &
Judgment
Filings		 Tax
Lien
Filings
6/30/202412/31/2023YesYes-YesYes

Industries
SIC Code Description
2836 Biological products, except diagnostic substances
8731 Commercial physical and biological research
2834 Pharmaceutical preparations

Officers and Directors

Title
Name
Age		 Title
Date		 Start
Date
Chairman of the Board, Chief Executive Officer VuongTrieu 57 1/1/2021 4/22/2019
Chief Financial Officer Amit B.Shah 55 7/1/2019 7/1/2019
Chief Medical Officer - Translation Medicine, Director Anthony E.Maida 69 5/11/2020 4/1/2020
3 additional Officers and Directors records available in full report.

Subsidiaries
Business Name Address City State/Province Country
PointR Data Inc. 960 Saratoga Ave. San Jose CA United States

Business Names
Business Name
MATN
Oncotelic Inc.
OTLC
5 additional Business Names available in full report.

General Information
Number of Employees: 22 (As of 12/31/2023)
Outstanding Shares: 406,270,315 (As of 8/11/2024)
Shareholders: 79
Stock Exchange: OTC
Federal Tax Id: 133679168
Fax Number: (650) 635-7001


Copyright © 2024 CreditRiskMonitor.com (Ticker: CRMZ). All rights reserved.     
By using this website, you accept the Terms of Use Agreement.
Wednesday, November 20, 2024